Laureates: All
Here is the list of the laureates from 1994 to today
Year | Prix Galien Research | Prix Galien Innovative Product |
2022 | N/A | Takhzyro (lanedelumab injection) Takeda Canada Inc. |
Year | Prix Galien COVID-19 Award | Prix Galien Innovative Product |
2020 | MEDICAGO | Patisiran (ONPATTRO) Alnylam Pharmaceuticals |
| Year | Prix Galien Research | Prix Galien Innovative Product |
| 2019 | DR. SUSAN GEORGE, DR. BRIAN O'DOWD, DR. GREGORY A. DEMOPULOS, DR. GEORGE A. GAITANARIS, DR. ALEXANDER GRAGEROV | SHINGRIX (Recombinant Zoster Vaccine) GSK |
| 2018 | N/A | SACUBITRIL/VALSARTAN (Entresto) Novartis Pharmaceuticals Canada Inc. |
| 2017 | DR. ERNESTO SCHIFFRIN (McGill University) | KEYTRUDA (pembrolizumab) Merck Canada |
| 2016 | DR. PHILIP F. HALLORAN OC, MD, PhD, FRCPC, FRSC | HARVONI (Sofosbuvir/Ledipasvir) Gilead Sciences Canada ENTYVIO (Vedolizumab) Takeda Canada |
| 2015 | DR. JOHN KELTON, DR. THEODORE WARKENTIN | afatinib (Giotrif) (Boehringer-Ingelheim Canada) |
| 2014 | DR. BRETT FINLAY (University of British Columbia) | PIRFENIDONE (ESBRIET) InterMune Canada (Roche)) |
| 2013 | DR. FRANCIS ALLAN PLUMMER (University of Manitoba) | (YERVOY) IPILIMUMAB (Bristol Myers Squibb Canada) |
2012 | DR. ROBERT E. W. HANCOCK (University of British Columbia) | INCIVEK (TELAPREVIR) (Vertex Canada Ltd) VICTRELIS (BOCEPRIVIR) (Merck Canada Inc.) |
2011 | DR. PIETER R. CULLIS (University of British Columbia) | PRADAX (Boehringer Ingelheim Canada) |
| 2010 | DR. JULIO S. G. MONTANER (BC Center for Excellence in HIV/AIDS) | STELARA (Janssen-Ortho) |
| 2009 | DR. DONALD F. WEAVER (University of Dalhousie) | CHAMPIX (Pfizer Canada inc.) |
| 2008 | DR. DANIEL J. DRUCKER (University of Toronto) | GARDASIL (Merck Frosst Canada) |
| 2007 | DR. MICHAEL HAYDEN (University of British Columbia) | |
| 2006 | DR. HAROLD JENNINGS (National Research Council Canada) | |
| 2005 | DR. LORNE BABIUK (University of Sakatchewan) | |
| 2004 | DR. PAUL ARMSTRONG (Faculty of medecine, University of Alberta) | SPIRIVA (Boehringer Ingelheim Canada) |
| 2003 | DR. MARK A. WAINBERG (Jewish General Hospital – Sir Mortimer B. Davis) | GLEEVEC (Novartis Pharma Canada) |
| 2002 | DRS. JULIA LEVEY et DAVID DOLPHIN (University of British Columbia ) and (ex aequo) DR ANTONY J. PAWSON (University of Toronto ) | ENBREL (Wyeth-Ayerst Canada) |
| 2001 | DR. SALIM YUSUF (Research Centre of the Hamilton Civic Hospital) | VIAGRA (Pfizer) |
| 2000 | MONTELUKAST SODIUM RESEARCH TEAM SUR LE (Merck Frosst) | SINGULAIR (Merck Frosst) |
| 1999 | DR. JACK HIRSH (Research Centre of the Hamilton Civic Hospital ) | LIPITOR (Parke-Davis Canada) |
| 1998 | DRS. LORNE TYRRELL and MORRIS ROBIN (University ofEdmonton Alberta) | FOSAMAX (Merck Frosst Canada) |
| 1997 | DRS. SERGE GAUTHIER, JUDES POIRIER et RÉMI QUIRION (McGill University and Research Centre of the Douglas Hospital ) | 3TC (découvert par BioChem Pharma et développé par Glaxo Wellcome) |
| 1996 | ANTIVIRAL COMPOUNDS RESEARCH TEAM (BioChem Pharma) | SABRIL (Marion Merrell Dow) |
| 1995 | DR. PETER SCHILLER (IRCM) | RISPERDAL (Janssen Pharmaceutical) |
| 1994 | DRS. PHILIP SEEMAN, HYMAN NIZNIK et HUBERT VAN TOL (University of Toronto) | IMMITREX (Glaxo Canada) |